Details
Stereochemistry | ACHIRAL |
Molecular Formula | C17H21NO.C6H8O7 |
Molecular Weight | 447.4783 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CN(C)CCOC1=CC=CC=C1CC2=CC=CC=C2
InChI
InChIKey=ZZYHCCDMBJTROG-UHFFFAOYSA-N
InChI=1S/C17H21NO.C6H8O7/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-11H,12-14H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
Molecular Formula | C6H8O7 |
Molecular Weight | 192.1235 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C17H21NO |
Molecular Weight | 255.3547 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Phenyltoloxamine is an ethanolamine derivative with antihistaminic property, which is used in combination with some analgesics for the temporary relief of minor aches and pains associated with headache; backache; muscular aches; temporarily reduces fever and some others disorders. Phenyltoloxamine blocks H1 histamine receptor, thereby inhibiting phospholipase A2 and production of endothelium-derived relaxing factor, nitric oxide. Subsequent lack of activation of guanylyl cyclase through nitric oxide results in decreased cyclic GMP levels, thereby inhibiting smooth muscle constriction of various tissues, decreasing capillary permeability and decreasing other histamine-activated allergic reactions.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL231 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8227466 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Bristalin Approved UsePhenyltoloxamine is a first generation antihistamine that is used for symptoms of the common cold and as a short acting sedative. Launch Date1951 |
|||
Primary | DOLOGESIC Approved UseUnknown |
|||
Palliative | DOLOGESIC Approved UseUnknown |
|||
Palliative | DOLOGESIC Approved UseUnknown |
|||
Palliative | DOLOGESIC Approved UseUnknown |
Sample Use Guides
adults and children 12 years of age and older: take 1 or 2 tablespoons of DOLOGESIC (acetaminophen, phenyltoloxamine citrate, alcohol liquid); every 4 to 6 hours.
children under 12 years of age: Consult a physician; do not give this product to children under 12 years of age. This product will provide more than the recommended dose (overdose) of non-aspirin and could cause serious health problems
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:24:33 GMT 2025
by
admin
on
Mon Mar 31 18:24:33 GMT 2025
|
Record UNII |
8UE48MJH8M
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8UE48MJH8M
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
14440
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
100000085281
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
1534402
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
214-644-7
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
1176-08-5
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
DBSALT001531
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
169860
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
DTXSID5047790
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
8UE48MJH8M
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
221141
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB03784MIG
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
C82275
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | |||
|
m8695
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL186720
Created by
admin on Mon Mar 31 18:24:33 GMT 2025 , Edited by admin on Mon Mar 31 18:24:33 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |